Scholars Central

ArticlePublished 28 Jul 2025

Identification of Impurities in the Drug Risankizumab Using RP-HPLC Method

Authors: U. Harini, S. Purnakala

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: To establish and validate a stability-indicating RP-HPLC method for the concurrent quantification of Risankizumab and its associated impurities in both bulk drug substances and pharmaceutical dosage forms. Specific objectives: • To develop a simple, rapid and specific RP-HPLC method for the estimation of Risankizumab and its impurities in bulk and combined pharmaceutical dosage forms. • To validate the proposed methods in accordance with the analytical parameters mentioned in the ICH guidelines, such as system suitability, accuracy, precision, specificity, linearity, robustness, LOD and LOQ. • To develop the method under the forced conditions such as acid, alkali, peroxide, reduction, thermal, hydrolysis and photo degradation. A simple, rapid, precise, sensitive and reproducible Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method has been developed for the quantitative analysis of Risankizumab and its impurities in pharmaceutical dosage form. Chromatographic separation of Risankizumab and its impurities was achieved on waters alliance-e2695, by using Luna Phenyl Hexyl 150 mm × 4.6 mm, 5 µ column and the mobile phase containing 0.1% TEA pH-2.5/OPA and Acetonitrile in the ratio of 80:20% v/v. The flow rate was 1 ml/min; detection was carried out by absorption at 263 nm using a photodiode array detector at ambient temperature. The number of theoretical plates for Risankizumab and its impurities was not less than 2000 and the tailing factor did not exceed 2. The % Relative Standard Deviation (%RSD) of peak areas across all measurements remained below 2.0. The developed method was validated in accordance with ICH guidelines. It proved to be a simple, cost-effective, precise, accurate, robust and suitable approach for the quantitative determination of Risankizumab and its impurities, as well as for conducting stability studies.details summary { cursor: pointer; color: #f8f9fa; } a { font-size: 11px; opacity: 0.5; }ReferencesFind Lawyer in Oregon Blog | Eye Surgery Journals

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Drug and Alcohol Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Drug and Alcohol Research
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “U. Harini”
  • BylineArticles whose byline prints “S. Purnakala”